SELLAS Life Sciences Group Inc buy Quitte
Start price
25.02.15
/
50%
€47,520
Target price
05.03.15
€55,500
Performance (%)
18.18%
End price
05.03.15
€56,160
Summary
This prediction ended on 05.03.15 with a price of €56,160. The BUY prediction by Quitte finished with a performance of 18.18%. Quitte has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 7.327% | 7.327% | -27.151% | -85.469% |
| iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
| iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
| iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
| iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |
Comments by Quitte for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
das Huhn fliegt noch
nachdem das Hühnchen gestern ziemlich gerupft wurde, setze ich doch auf einen Rest Flugfähigkeit ;-)
und wenn die Henne nicht fliegt, wird sie wenigstens auf die nächst höhere Stange hüpfen.